IF YOU PURCHASED THERANOS BLOOD TESTING SERVICES, YOU MAY BE ENTITLED TO A CASH PAYMENT FROM A CLASS ACTION SETTLEMENT.

Para una notifcación en Español, haga clic AQUI.

What is this lawsuit about?

Settlements have been reached in a class action lawsuit arising out of Theranos blood testing services marketed to consumers in Walgreens retail stores in Arizona and California. 

The lawsuit, In re Arizona Theranos, Inc., Litigation, Case No. 2:16-cv-2138, received Final Approval in the U.S. District Court for the District of Arizona on February 6, 2024. The Class Members have reached settlements with Defendants Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. (together called “Walgreens”), Defendant Ramesh (“Sunny”) Balwani, and the entity that holds the remaining assets of the now-dissolved Theranos, Inc. (the “Theranos ABC”). Walgreens and Balwani deny all allegations in the lawsuit. The Court has not decided who is right or wrong. The parties have agreed to the settlements to avoid the expense, uncertainty, and risks associated with litigation.

Under the settlement with Walgreens, Walgreens must pay $44 million into a Settlement Fund, which will be used to pay Class Members after deducting administration costs, attorneys’ fees and expenses and any service awards for the class representatives, taxes and tax expenses, and any other Court-approved deductions. In addition, Mr. Balwani has agreed to withdraw his claims to the remaining assets of Theranos, and the Theranos ABC has agreed to allocate a portion of the limited remaining Theranos assets to the Class, which will add approximately $1.33 million to the money available for distribution to the Class and increase the settlement payment amounts for Class Members. Class Members will receive payments that are based on the costs of their Theranos blood testing services, with some adjustments. See FAQ 11 and FAQ 12 for details.​​​​​

Who is included?

The Court previously certified a Class and three Subclasses in this case. Notice about the Court’s decision to certify the Class and Subclasses was provided to the Class in 2022 by mail, email, and other means.  A second notice was sent in November 2023, this time about the settlements. If you received a notice about the settlements by mail or email, then Theranos’s records indicate that you are a member of the Class and one or more of the Subclasses. The Class and Subclasses are defined in FAQ 4.

If your name and address were correct on your Notice, you did not need to take any action to receive a check from this settlement. You can view the estimated amount of your settlement payment and, if the name or address information on your Notice are incorrect, you may update your contact information by visiting the Update Contact Information/View Payment Estimate page of this website.